Short interest for Seres Therapeutics gives investors a sense of the degree to which investors are betting on the decline of Seres Therapeutics's stock. Short interest data is updated every two weeks.

Seres Therapeutics Stock (NASDAQ:MCRB), Short Interest Report

Seres Therapeutics

Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.

News

Penny Stocks

Price Target

Small Cap

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

CHPT

COOK

CRWD

MCRB

ROST

TWLO

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Emerson Electric To Rally More Than 19%? Here Are 10 Top Analyst Forecasts For Wednesday

Biotech

Earnings

Guidance

Health Care

Movers

General

Seres Therapeutics Inc (NASDAQ: MCRB) received FDA Fast Track Designation for SER-155, an investigational oral, cultivated microbiome therapeutic designed to prevent GI-associated bacterial infections and to reduce the incidence of severe acute graft-versus-host disease in immunocompromised patients un

Why Is Microbiome-Based Seres Therapeutics Stock Trading Higher Today?

Eurozone

Commodities

Global

Intraday Update

BETS

EFTR

GRFS

GRTX

SNTG

U.S. stocks traded lower this morning, with the Dow Jones falling more than 200 points on Tuesday.

Following the market opening Tuesday, the Dow traded down 0.63% to 37,445.51 while the NASDAQ fell 0.66% to 14,745.96. The S&amp;P 500 also fell, dropping, 0.55% to 4,737.17.

Dow Tumbles Over 200 Points; US Trade Gap Narrows In November

Seres Therapeutics Inc

Seres Therapeutics Concludes Enrollment In Cohort 2 Of Phase 1B Trial Of SER-155 In Allogeneic Hematopoietic Stem Cell Transplant Patients; Clinical Data Readout Expected End Of Q3 2024

Seres Therapeutics Announced That On March 25, 2024, The Compensation And Talent Committee Of Seres' Board Of Directors Granted Inducement Equity Grants Of 700,000 Shares To Marella Thorell, New Executive Vice President And CFO

Oppenheimer analyst Jeff Jones maintains Seres Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRB#NASDAQ">MCRB</a>) with a Outperform and lowers the price target from $9 to $5.

Oppenheimer Maintains Outperform on Seres Therapeutics, Lowers Price Target to $5

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-ratings/">analyst ratings page</a>.
<ul>
<li>Morgan Stanley boosted the price target for Sea Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/se#NYSE">SE</a>) from $47 to $65. Morgan Stanley analyst Mark Goodridge maintained an Equal-Weight rating. Sea shares gained 3.4% to close at $55.75 on Tuesday. <a href="https://www.benzinga.com/quote/SE/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Barclays raised the price target for Target Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tgt#NYSE">TGT</a>) from $142 to $169. Barclays analyst Seth Sigman maintained an Equal-Weight rating. Target shares jumped 12% to close at $168.58 on Tuesday. <a href="https://www.benzinga.com/quote/TGT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Chardan Capital lowered Seres Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mcrb#NASDAQ">MCRB</a>) price target from $10 to $8. Chardan Capital analyst Keay Nakae maintained a Buy rating. Seres Therapeutics shares fell 7% to close at $1.06 on Tuesday. <a href="https://www.benzinga.com/quote/MCRB/analyst-ratings">See how other analysts view this stock.</a></li>
<li>B of A Securities boosted the price target for Nordstrom, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/jwn#NYSE">JWN</a>) from $13 to $15. B of A Securities analyst Lorraine Hutchinson maintained an Underperform rating. Nordstrom shares gained 1.6% to close at $20.90 on Tuesday. <a href="https://www.benzinga.com/quote/JWN/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Needham cut ChargePoint Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/chpt#NYSE">CHPT</a>) price target from $4 to $3. Needham analyst Chris Pierce maintained a Buy rating. ChargePoint shares fell 3.4% to close at $2.00 on Monday. <a href="https://www.benzinga.com/quote/CHPT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Keybanc boosted the price target for CrowdStrike Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/crwd#NASDAQ">CRWD</a>) from $375 to $430. Keybanc analyst Eric Heath maintained an Overweight rating. CrowdStrike shares fell 5.2% to close at $297.56 on Tuesday. <a href="https://www.benzinga.com/quote/CRWD/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Wells Fargo slashed Twilio Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/twlo#NYSE">TWLO</a>) price target from $70 to $60. Wells Fargo analyst Michael Turrin maintained an Equal-Weight rating. Twilio shares fell 5.9% to close at $56.66 on Tuesday. <a href="https://www.benzinga.com/quote/TWLO/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Guggenheim boosted Ross Stores, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rost#NASDAQ">ROST</a>) price target from $140 to $165. Guggenheim analyst Robert Drbul maintained a Buy rating. Ross Stores shares fell 0.5% to close at $149.17 on Tuesday. <a href="https://www.benzinga.com/quote/ROST/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Canaccord Genuity cut Traeger, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cook#NYSE">COOK</a>) price target from $5 to $4. Canaccord Genuity analyst Brian McNamara maintained a Buy rating. Traeger shares fell 4.2% to close at $2.06 on Tuesday. <a href="https://www.benzinga.com/quote/COOK/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Berenberg raised Emerson Electric Co. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/emr#NYSE">EMR</a>) price target from $100 to $130. Berenberg analyst Philip Buller maintained a Buy rating. Emerson Electric shares fell 0.5% to close at $109.02 on Tuesday. <a href="https://www.benzinga.com/quote/EMR/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
&nbsp;
Check This Out: <a href="https://www.benzinga.com/news/24/03/37505931/top-2-utilities-stocks-that-may-fall-off-a-cliff-in-q1"> Top 2 Utilities Stocks That May Fall Off A Cliff In Q1 </a>

Chardan Capital analyst Keay Nakae maintains Seres Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRB#NASDAQ">MCRB</a>) with a Buy and lowers the price target from $10 to $8.

Chardan Capital Maintains Buy on Seres Therapeutics, Lowers Price Target to $8

Seres' $128M In Cash Balance, Planned Savings From Restructuring Announced In November 2023, And, Assuming Continued Revenue Growth Of Vowst, Expected Receipt Of The $45M Tranche B Under Its Secured Debt Will Support Its Operations Into Q4 2024

Seres Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRB#NASDAQ">MCRB</a>) reported quarterly losses of $(0.89) per share which beat the analyst consensus estimate of $(0.96) by 7.29 percent. This is a 61.47 percent increase over losses of $(2.31) per share from the same period last year. The company reported quarterly sales of $126.33 million which beat the analyst consensus estimate of $126.07 million by 0.21 percent. This is a 1.67K percent increase over sales of $7.13 million the same period last year.

Seres Therapeutics FY GAAP EPS $(0.89) Beats $(0.96) Estimate, Sales $126.33M Beat $126.07M Estimate

<h3>Companies Reporting Before The Bell</h3>
&bull; NIO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) is estimated to report quarterly loss at $0.51 per share on revenue of $2.29 billion.
&bull; Target (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) is estimated to report quarterly earnings at $2.22 per share on revenue of $29.33 billion.
&bull; 2seventy bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSVT#NASDAQ">TSVT</a>) is expected to report quarterly loss at $0.99 per share on revenue of $14.71 million.
&bull; CLPS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLPS#NASDAQ">CLPS</a>) is expected to report earnings for its first quarter.
&bull; Seres Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRB#NASDAQ">MCRB</a>) is projected to report quarterly loss at $0.50 per share on revenue of $350 thousand.
&bull; Vivid Seats (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEAT#NASDAQ">SEAT</a>) is expected to report quarterly earnings at $0.06 per share on revenue of $183.67 million.
&bull; Nuwellis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) is projected to report quarterly loss at $1.39 per share on revenue of $2.55 million.
&bull; Consolidated Comms Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNSL#NASDAQ">CNSL</a>) is likely to report quarterly loss at $0.36 per share on revenue of $276.94 million.
&bull; CECO Environmental (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CECO#NASDAQ">CECO</a>) is likely to report quarterly earnings at $0.24 per share on revenue of $146.61 million.
&bull; 908 Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASS#NASDAQ">MASS</a>) is expected to report quarterly loss at $0.26 per share on revenue of $14.16 million.
&bull; Neuronetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STIM#NASDAQ">STIM</a>) is projected to report quarterly loss at $0.26 per share on revenue of $19.85 million.
&bull; Broadwind (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BWEN#NASDAQ">BWEN</a>) is expected to report quarterly earnings at $0.00 per share on revenue of $50.15 million.
&bull; Global Business Travel (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GBTG#NYSE">GBTG</a>) is projected to report quarterly loss at $0.03 per share on revenue of $541.17 million.
&bull; Riskified (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RSKD#NYSE">RSKD</a>) is likely to report quarterly earnings at $0.03 per share on revenue of $84.02 million.
&bull; Angel Oak Mortgage REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AOMR#NYSE">AOMR</a>) is expected to report quarterly earnings at $0.18 per share on revenue of $9.00 million.
&bull; L.B. Foster (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSTR#NASDAQ">FSTR</a>) is expected to report quarterly earnings at $0.01 per share on revenue of $129.35 million.
&bull; Rand Capital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAND#NASDAQ">RAND</a>) is expected to report earnings for its fourth quarter.
&bull; Dave (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DAVE#NASDAQ">DAVE</a>) is likely to report earnings for its fourth quarter.
&bull; Sophia Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOPH#NASDAQ">SOPH</a>) is projected to report quarterly loss at $0.26 per share on revenue of $17.33 million.
&bull; First Watch Restaurant Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FWRG#NASDAQ">FWRG</a>) is expected to report quarterly earnings at $0.04 per share on revenue of $237.53 million.
&bull; Compugen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGEN#NASDAQ">CGEN</a>) is likely to report quarterly earnings at $0.22 per share on revenue of $20.00 million.
&bull; SmartRent (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMRT#NYSE">SMRT</a>) is likely to report quarterly loss at $0.01 per share on revenue of $59.49 million.
&bull; Ferguson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FERG#NYSE">FERG</a>) is estimated to report quarterly earnings at $1.85 per share on revenue of $6.77 billion.
&bull; Cipher Mining (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CIFR#NASDAQ">CIFR</a>) is estimated to report quarterly loss at $0.04 per share on revenue of $41.78 million.
&bull; Axogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXGN#NASDAQ">AXGN</a>) is likely to report quarterly loss at $0.10 per share on revenue of $41.65 million.
&bull; V2X (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VVX#NYSE">VVX</a>) is expected to report quarterly earnings at $0.33 per share on revenue of $1.01 billion.
&bull; Wag Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PET#NASDAQ">PET</a>) is likely to report earnings for its fourth quarter.
&bull; Myers Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MYE#NYSE">MYE</a>) is expected to report quarterly earnings at $0.26 per share on revenue of $196.19 million.
<h3>Companies Reporting After The Bell</h3>
&bull; Fabrinet (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FN#NYSE">FN</a>) is estimated to report quarterly earnings at $0.80 per share on revenue of $197.70 million.
&bull; Nordstrom (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JWN#NYSE">JWN</a>) is estimated to report quarterly earnings at $0.88 per share on revenue of $4.39 billion.
&bull; BlackRock Cap Inv (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKCC#NASDAQ">BKCC</a>) is likely to report quarterly earnings at $0.12 per share on revenue of $20.32 million.
&bull; Presto Automation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRST#NASDAQ">PRST</a>) is likely to report earnings for its fourth quarter.
&bull; Kingsway Financial Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KFS#NYSE">KFS</a>) is likely to report earnings for its fourth quarter.
&bull; Emergent BioSolutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) is expected to report quarterly loss at $0.19 per share on revenue of $293.53 million.
&bull; Cumberland (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPIX#NASDAQ">CPIX</a>) is likely to report earnings for its fourth quarter.
&bull; TRACON Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCON#NASDAQ">TCON</a>) is likely to report quarterly loss at $0.08 per share on revenue of $1.00 million.
&bull; Entravision Comms (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVC#NYSE">EVC</a>) is projected to report quarterly earnings at $0.07 per share on revenue of $308.47 million.
&bull; Bionano Genomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNGO#NASDAQ">BNGO</a>) is projected to report quarterly loss at $0.87 per share on revenue of $10.58 million.
&bull; Inspirato (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPO#NASDAQ">ISPO</a>) is likely to report quarterly loss at $3.66 per share on revenue of $73.50 million.
&bull; Marinus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNS#NASDAQ">MRNS</a>) is expected to report quarterly loss at $0.62 per share on revenue of $8.01 million.
&bull; Allient (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNT#NASDAQ">ALNT</a>) is expected to report quarterly earnings at $0.32 per share on revenue of $132.56 million.
&bull; Bristow Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTOL#NYSE">VTOL</a>) is projected to report quarterly earnings at $0.54 per share on revenue of $329.20 million.
&bull; Greenlight Capital Re (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLRE#NASDAQ">GLRE</a>) is estimated to report earnings for its fourth quarter.
&bull; Rigel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIGL#NASDAQ">RIGL</a>) is estimated to report quarterly loss at $0.03 per share on revenue of $34.10 million.
&bull; Plus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) is projected to report quarterly loss at $1.07 per share on revenue of $1.06 million.
&bull; Socket Mobile (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCKT#NASDAQ">SCKT</a>) is estimated to report quarterly loss at $0.06 per share on revenue of $4.91 million.
&bull; Nyxoah (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NYXH#NASDAQ">NYXH</a>) is expected to report quarterly loss at $0.40 per share on revenue of $1.95 million.
&bull; Park-Ohio Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PKOH#NASDAQ">PKOH</a>) is likely to report quarterly earnings at $0.55 per share on revenue of $386.45 million.
&bull; W&amp;T Offshore (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WTI#NYSE">WTI</a>) is expected to report quarterly earnings at $0.01 per share on revenue of $138.42 million.
&bull; Cadre Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CDRE#NYSE">CDRE</a>) is projected to report quarterly earnings at $0.18 per share on revenue of $121.79 million.
&bull; Semler Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMLR#NASDAQ">SMLR</a>) is expected to report quarterly earnings at $0.57 per share on revenue of $14.50 million.
&bull; Agiliti (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGTI#NYSE">AGTI</a>) is projected to report quarterly earnings at $0.11 per share on revenue of $291.41 million.
&bull; Nuvei (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVEI#NASDAQ">NVEI</a>) is projected to report quarterly earnings at $0.45 per share on revenue of $319.51 million.
&bull; Franco-Nevada (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FNV#NYSE">FNV</a>) is estimated to report quarterly earnings at $0.84 per share on revenue of $283.00 million.
&bull; Mayville Engineering (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MEC#NYSE">MEC</a>) is projected to report quarterly earnings at $0.13 per share on revenue of $152.30 million.
&bull; Aquestive Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AQST#NASDAQ">AQST</a>) is likely to report quarterly loss at $0.08 per share on revenue of $11.63 million.
&bull; Orthofix Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OFIX#NASDAQ">OFIX</a>) is expected to report earnings for its fourth quarter.
&bull; MeridianLink (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MLNK#NYSE">MLNK</a>) is estimated to report quarterly loss at $0.13 per share on revenue of $74.86 million.
&bull; Ross Stores (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROST#NASDAQ">ROST</a>) is likely to report earnings for its fourth quarter.
&bull; Cerus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERS#NASDAQ">CERS</a>) is expected to report quarterly loss at $0.02 per share on revenue of $49.27 million.
&bull; American Public Education (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APEI#NASDAQ">APEI</a>) is projected to report quarterly earnings at $0.14 per share on revenue of $150.47 million.
&bull; Cricut (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRCT#NASDAQ">CRCT</a>) is estimated to report quarterly earnings at $0.05 per share on revenue of $249.68 million.
&bull; Crexendo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CXDO#NASDAQ">CXDO</a>) is projected to report quarterly earnings at $0.04 per share on revenue of $13.80 million.
&bull; Aeva Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEVA#NYSE">AEVA</a>) is likely to report quarterly loss at $0.15 per share on revenue of $1.57 million.
&bull; LSB Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LXU#NYSE">LXU</a>) is estimated to report quarterly earnings at $0.04 per share on revenue of $127.21 million.
&bull; PlayAGS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGS#NYSE">AGS</a>) is projected to report quarterly earnings at $0.03 per share on revenue of $92.57 million.
&bull; Full House Resorts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLL#NASDAQ">FLL</a>) is likely to report quarterly loss at $0.14 per share on revenue of $63.13 million.
&bull; CrowdStrike Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) is expected to report quarterly earnings at $0.82 per share on revenue of $839.04 million.
&bull; HashiCorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCP#NASDAQ">HCP</a>) is expected to report quarterly earnings at $0.01 per share on revenue of $149.29 million.
&bull; Banco BBVA Argentina (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBAR#NYSE">BBAR</a>) is estimated to report earnings for its fourth quarter.
&bull; NeuroPace (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NPCE#NASDAQ">NPCE</a>) is expected to report quarterly loss at $0.31 per share on revenue of $17.46 million.
&bull; Couchbase (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BASE#NASDAQ">BASE</a>) is projected to report earnings for its fourth quarter.
&bull; Ooma (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OOMA#NYSE">OOMA</a>) is likely to report quarterly earnings at $0.12 per share on revenue of $61.46 million.
&bull; ChargePoint Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHPT#NYSE">CHPT</a>) is likely to report quarterly loss at $0.13 per share on revenue of $119.59 million.
&bull; ODDITY Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODD#NASDAQ">ODD</a>) is expected to report earnings for its fourth quarter.
&bull; NewtekOne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEWT#NASDAQ">NEWT</a>) is projected to report quarterly earnings at $0.58 per share on revenue of $63.35 million.
&bull; Box (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOX#NYSE">BOX</a>) is expected to report quarterly earnings at $0.38 per share on revenue of $262.95 million.
&bull; Weyco Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WEYS#NASDAQ">WEYS</a>) is projected to report earnings for its fourth quarter.
&bull; Alexandria Real Estate (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARE#NYSE">ARE</a>) is likely to report earnings for its fourth quarter.
This article was generated by Benzinga&#39;s automated content engine and reviewed by an editor.

AEVA

AGTI

ALNT

AOMR

APEI

AQST

AXGN

BASE

BBAR

BKCC

BNGO

BWEN

CDRE

CECO

CERS

CGEN

CIFR

CLPS

CNSL

CPIX

CRCT

CXDO

DAVE

FERG

FSTR

FWRG

GBTG

GLRE

ISPO

MASS

MLNK

MRNS

NEWT

NPCE

NUWE

NVEI

NYXH

OFIX

OOMA

PKOH

PRST

PSTV

RAND

RIGL

RSKD

SCKT

SEAT

SMLR

SMRT

SOPH

STIM

TCON

TSVT

VTOL

WEYS

Earnings Scheduled For March 5, 2024

Seres Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRB#NASDAQ">MCRB</a>) is set to give its latest quarterly earnings report on Tuesday, 2024-03-05. Here's what investors need to know before the announcement.
Analysts estimate that Seres Therapeutics will report an earnings per share (EPS) of $-0.50. 
Seres Therapeutics bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Past Earnings Performance</h3>
Last quarter the company beat EPS by $0.13, which was followed by a 39.43% increase in the share price the next day.
Here's a look at Seres Therapeutics's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.50</td>
<td>0.55</td>
<td>-0.55</td>
<td>-0.46</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.37</td>
<td>0.36</td>
<td>-0.57</td>
<td>-0.54</td>
</tr>
<tr>
<td>Price Change %</td>
<td>39.0%</td>
<td>-6.0%</td>
<td>-5.0%</td>
<td>10.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1709568159_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Seres Therapeutics were trading at $1.23 as of March 01. Over the last 52-week period, shares are down 78.52%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. 
<a href="https://www.benzinga.com/quote/MCRB/earnings">To track all earnings releases for Seres Therapeutics visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Seres Therapeutics's Earnings: A Preview

Management

Seres Therapeutics Announced That Marella Thorell Will Join As Executive Vice President And Chief Financial Officer, As Of March 25, Following David Arkowitz's Retirement

Seres Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRB#NASDAQ">MCRB</a>) (&quot;Seres&quot; or the &quot;Company&quot;), a leading microbiome therapeutics company, today announced that on January 10, 2024, the Compensation and Talent Committee of Seres&#39; board of directors granted inducement equity grants covering an aggregate of 67,500 shares of its common stock to one new employee, consisting of stock options to purchase 45,000 shares of common stock and restricted stock units (&quot;RSUs&quot;) covering 22,500 shares of its common stock.

Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Oppenheimer analyst Jeff Jones maintains Seres Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRB#NASDAQ">MCRB</a>) with a Outperform and lowers the price target from $10 to $9.

Oppenheimer Maintains Outperform on Seres Therapeutics, Lowers Price Target to $9

Seres Therapeutics Inc&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mcrb#NASDAQ">MCRB</a>) received FDA Fast Track Designation for SER-155, an investigational oral, cultivated microbiome therapeutic designed to prevent GI-associated bacterial infections and to reduce the incidence of severe acute graft-versus-host disease in immunocompromised patients undergoing allogeneic&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/pressreleases/24/01/b36552641/seres-therapeutics-announces-vowst-commercial-launch-update-and-us-fda-fast-track-designation-for-" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">hematopoietic stem cell transplantation</a>.
<ul>
<li>SER-155 Phase 1b Cohort 1 clinical data showed favorable tolerability, successful drug bacteria engraftment, and a substantial reduction in pathogen domination in the gastrointestinal microbiome, supporting progression to the placebo-controlled Cohort 2.</li>
<li>SER-155 Phase 1b placebo-controlled Cohort 2 data readout is anticipated in the third quarter of 2024.</li>
<li>Seres anticipates that a 2023 year-end cash balance of $128 million, in conjunction with the anticipated savings from the restructuring announced in November 2023 and the expected receipt of the $45 million Tranche B under its existing senior secured debt facility with Oaktree Capital Management, will support its operations into Q4 of 2024.</li>
</ul>
The company also announced preliminary key VOWST (fecal microbiota spores, live-brpk) launch metrics.
VOWST, the first FDA-approved orally administered microbiome therapeutic, received FDA approval in April of 2023 and is indicated to prevent the recurrence of Clostridioides difficile infection (CDI) in adults following antibacterial&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/general/biotech/23/04/32039050/why-seres-therapeutics-shares-are-surging-thursday-morning" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">treatment for recurrent CDI (rCDI)</a>.&nbsp;
VOWST Commercial Performance
<ul>
<li>Preliminary Q4 net sales were approximately $10.4 million and reflected a gross-to-net reduction of 11%. Total 2023 net sales since launch in June were approximately $19.6 million and reflected a gross-to-net reduction of 13%.</li>
<li>Q4 completed prescription enrollment forms received for VOWST were 1,322; 1,082 resulted in new patient starts by year-end 2023.</li>
<li>The total 2023 completed prescription enrollment forms received for VOWST since launch were 2,833; of those, 2,015 resulted in new patient starts by year-end 2023.</li>
<li>In 2023, prescription enrollment forms were submitted by approximately 1,330 unique healthcare providers since launch; approximately 340 HCPs have prescribed VOWST to more than one patient.</li>
</ul>
Price Action:&nbsp;MCRB shares are up 11.5% at $1.740 on the last check Tuesday.

U.S. stocks traded lower this morning, with the Dow Jones falling more than 200 points on Tuesday.
Following the market opening Tuesday, the Dow traded down 0.63% to 37,445.51 while the NASDAQ fell 0.66% to 14,745.96. The S&amp;P 500 also fell, dropping, 0.55% to 4,737.17.
Check This Out: <a href="https://www.benzinga.com/news/earnings/24/01/36550820/how-to-earn-500-a-month-from-bank-of-america-stock-ahead-of-q4-earnings-report"> How To Earn $500 A Month From Bank of America Stock Ahead Of Q4 Earnings Report</a>
&nbsp;
<h3>Leading and Lagging Sectors</h3>
&nbsp;
Health care shares rose by just 0.01% on Tuesday.
In trading on Tuesday, real estate shares fell by 1.2%.
&nbsp;
<h3>Top Headline</h3>
&nbsp;
The US trade gap shrank to $63.2 billion in November from $64.5 billion in the previous month and compared to market estimates of a $65 billion gap.
&nbsp;
<h3>Equities Trading UP</h3>
&nbsp;
Sentage Holdings Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sntg#NASDAQ">SNTG</a>) shares shot up 108% to $4.42.
Shares of Galera Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/grtx#NASDAQ">GRTX</a>) got a boost, surging 27% to $0.1891.
Seres Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mcrb#NASDAQ">MCRB</a>) shares were also up, gaining 18% to $1.8465 after the company announced preliminary key VOWST launch metrics and FDA Fast Track Designation for SER-155.
&nbsp;
<h3>Equities Trading DOWN</h3>
&nbsp;
Grifols, S.A. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/grfs#NASDAQ">GRFS</a>) shares dropped 33% to $7.41 following a report from Gotham City Research titled &quot;Grifols SA: Scranton and the Undisclosed Debts.&quot;
Shares of eFFECTOR Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/eftr#NASDAQ">EFTR</a>) were down 23% to $0.4261 after the company announced a 1-for-25 reverse stock split.
Bit Brother Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bets#NASDAQ">BETS</a>) was down, falling 12% to $0.0057 after dipping 15% on Monday. Bit Brother announced a 1-for-1,000 reverse share split.
Also Check This Out:<a href="https://www.benzinga.com/trading-ideas/long-ideas/24/01/36550880/i-think-you-have-a-winner-and-it-is-just-on-fire-jim-cramer-on-this-brazilian-stock"> &#39;I Think You Have A Winner, And It Is Just On Fire&#39;: Jim Cramer On This Brazilian Stock</a>
&nbsp;
<h3>Commodities</h3>
&nbsp;
In commodity news, oil traded up 1.8% to $72.05 while gold traded up 0.6% at $2,046.10.
Silver traded up 0.4% to $23.41 on Tuesday while copper fell 0.4% to $3.7960.
&nbsp;
<h3>Euro zone</h3>
&nbsp;
European shares were lower today. The eurozone&rsquo;s STOXX 600 fell 0.5%, London&rsquo;s FTSE 100 fell 0.1% while Spain&rsquo;s IBEX 35 Index fell 2% The German DAX fell 0.5% French CAC 40 fell 0.6% while Italy&rsquo;s FTSE MIB Index fell 0.7%.
Industrial production in Germany fell 0.7% month-over-month in November versus a revised 0.3% decline in October. Retail sales in the UK increased 1.9% from a year ago in December.
Italy&#39;s unemployment rate fell to 7.5% in November versus a revised 7.7% in the previous month. French current account deficit shrank to EUR 2.8 billion in November 2023 versus a revised EUR 3.4 billion in the prior month, while trade deficit narrowed to &euro;5.9 billion in November versus a revised &euro;8.5 billion in the prior month.
&nbsp;
<h3>Asia Pacific Markets</h3>
&nbsp;
Asian markets closed mostly higher on Tuesday, with Japan&rsquo;s Nikkei 225 gaining 1.16%, Hong Kong&rsquo;s Hang Seng Index falling 0.21% and China&rsquo;s Shanghai Composite Index gaining 0.20%. India&rsquo;s S&amp;P BSE Sensex, meanwhile, rose 0.04%.
Household spending in Japan fell by 2.9% year-over-year in November following a 2.5% decline in the earlier month.
&nbsp;
<h3>Economics</h3>
&nbsp;
The NFIB Small Business Optimism Index rose to 91.9 in December from 90.6 in November.
The US trade gap shrank to $63.2 billion in November from $64.5 billion in the previous month and compared to market estimates of a $65 billion gap.
Now Read This: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/01/36550964/microsoft-blackrock-goldman-sachs-and-more-on-cnbcs-final-trades"> Microsoft, BlackRock, Goldman Sachs And More On CNBC&#39;s &#39;Final Trades&#39;</a>
&nbsp;

Seres Therapeutics shares are trading higher after the company announced preliminary key VOWST launch metrics and FDA Fast Track Designation for SER-155.

JNPR: 25% &#x7C;&nbsp;<a href="https://www.benzinga.com//node/36548871">Juniper Networks Surges Over 20% As Hewlett Packard Enterprise Reportedly Nears $13B Acquisition Deal</a>
MCRB: 44% &#x7C;&nbsp;<a href="https://www.benzinga.com//node/36553197">Seres Therapeutics Announces Vowst Preliminary Net Sales Of Approximately $10.4M (Unaudited) For Q4 Of 2023, Total 2023 Net Sales Since Launch In June Were Approximately $19.6M And Reflected A Gross-to-net Reduction Of 13%</a>
GRFS: -42% &#x7C;&nbsp;<a href="https://www.benzinga.com//node/36551039">Grifols Shares Down 42% Premarket; Gotham City Research Report: Grifols SA: Scranton and the Undisclosed Debts; Said Grifols Manipulates Reported Debt &amp; Ebitda To Artificially Reduce Reported Leverage To 6x Which We Believe Is Closer To 10x-13x</a>

JNPR

Market-Moving News for January 9th

<h3>Gainers</h3>
<ul>
<li>Aura Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AURA#NASDAQ">AURA</a>) stock moved upwards by 44.3% to $13.0 during Tuesday's pre-market session. The company's market cap stands at $640.3 million. </li>
<li>Galera Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRTX#NASDAQ">GRTX</a>) shares rose 40.01% to $0.21. The company's market cap stands at $11.3 million. </li>
<li>Jin Medical International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZJYL#NASDAQ">ZJYL</a>) stock moved upwards by 31.99% to $120.0. The company's market cap stands at $930.0 million. </li>
<li>Seres Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRB#NASDAQ">MCRB</a>) stock moved upwards by 26.91% to $1.98. The company's market cap stands at $255.9 million. </li>
<li>Lucy Scientific Discovery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSDI#NASDAQ">LSDI</a>) shares moved upwards by 22.83% to $0.24. The company's market cap stands at $4.2 million. </li>
<li>Elicio Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELTX#NASDAQ">ELTX</a>) shares increased by 22.37% to $9.57. The market value of their outstanding shares is at $91.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Grifols (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRFS#NASDAQ">GRFS</a>) shares declined by 35.2% to $7.21 during Tuesday's pre-market session. The company's market cap stands at $4.8 billion. </li>
<li>eFFECTOR Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EFTR#NASDAQ">EFTR</a>) stock fell 19.26% to $0.45. The company's market cap stands at $28.8 million. </li>
<li>Trevena (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRVN#NASDAQ">TRVN</a>) stock decreased by 10.25% to $0.66. The market value of their outstanding shares is at $10.0 million. </li>
<li>Apollomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLM#NASDAQ">APLM</a>) shares fell 10.05% to $0.84. The market value of their outstanding shares is at $74.8 million. </li>
<li>Societal CDMO (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCTL#NASDAQ">SCTL</a>) stock decreased by 9.19% to $0.34. The market value of their outstanding shares is at $36.1 million. </li>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) shares decreased by 8.47% to $2.92. The company's market cap stands at $2.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

APLM

AURA

CYCC

ELTX

LSDI

SCTL

TRVN

ZJYL

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

SER-155 Phase 1b placebo-controlled Cohort 2 data readout anticipated in&nbsp;third quarter&nbsp;of 2024

Seres Therapeutics Receives FDA Fast Track Designation For SER-155, Cultivated Microbiome Therapeutic Designed To Prevent GI-associated Bacterial Infections

Significant adoption of VOWST since commercial launch in June 2023 through year-end 2023 with 2,833 patient enrollment forms received and 2,015 new patient starts

Seres Therapeutics Announces Vowst Preliminary Net Sales Of Approximately $10.4M (Unaudited) For Q4 Of 2023, Total 2023 Net Sales Since Launch In June Were Approximately $19.6M And Reflected A Gross-to-net Reduction Of 13%

Reported Earlier, Seres Therapeutics To Present Preliminary PK/PD And Safety Data For Investigational Microbiome Therapeutic SER-155 At ASH 2023

Seres Therapeutics Q4 2023 Earnings Preview

Seres Therapeutics GAAP EPS of -$0.89 beats by $0.10, revenue of $126.33M beats by $0.23M

Seres Therapeutics Inc (MCRB) reported better than expected earnings this morning for Q4 2023.  reported that it broke-even during the quarter.   Revenues were downbeat at $0.00.  Keep in mind that the revenues reported were on an adjusted basis, so they may not be directly comparable to estimates and prior periods.The sto

Seres Therapeutics Inc Down 7.46% To $1.05 After Earnings

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Investors in gold are excited on Tuesday as the spot price of the precious metal hit a recent high of <a href="https://www.reuters.com/markets/commodities/gold-near-two-month-peak-anticipation-builds-june-us-rate-cut-2024-03-04/">$2,113.28 per ounce</a> during a rally yesterday.



The increasing price of gold is catching up to its current record high of $2,135.40 that was achieved in December 2023. To understand why gold is gaining lately, we have to look to the Federal Reserve.



Investors in gold are hoping that the Fed is done with interest rate increases. In fact, many are betting that the agency will drop interest rates starting in June. Considering the extra weight that high interest rates have had on the economy, this is welcome news for investors in both gold and the stock market.



<h2>Where Will the Price of Gold Go Next?</h2>



J.P.&nbsp;Morgan Research is predicting that gold prices will hit a <a href="https://www.jpmorgan.com/insights/global-research/commodities/gold-prices">new record high of $2,300 per ounce in 2025</a>. This is contingent on the Fed introducing 125 basis points of interest rate cuts over the second half of the year.



Gregory Shearer, Head of Base and Precious Metals Strategy at J.P.&nbsp;Morgan, said the following about gold prices.




&ldquo;We think over this period, the Fed cutting cycle and falling U.S. real yields will once again become the mono-driver behind gold&rsquo;s breakout rally later in 2024. Gold&rsquo;s inverse relationship to real yields has historically been weaker over Fed hiking cycles, before strengthening again as yields fall over a transition into a cutting cycle.&rdquo;




Investors will want to keep an eye on gold prices going forward alongside the rest of the stock market.



We can help with that as we have all of the hottest stock market news traders need to know about on Tuesday! That includes everything happening with Momentus&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/mnts-stock-quote/">MNTS</a>), Dorchester Minerals&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/dmlp-stock-quote/">DMLP</a>) and Seres Therapeutics&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/mcrb-stock-quote/">MCRB</a>) today. All of that news is ready at the links below!



<h2>More Tuesday Stock Market News</h2>



<ul><li><a href="https://investorplace.com/2024/03/mnts-stock-alert-momentus-snags-nasa-contract/">MNTS Stock Alert: Momentus Snags NASA Contract</a></li>



<li><a href="https://investorplace.com/earning-results/2024/03/dmlp-stock-earnings-dorchester-minerals-for-q4-of-2023/">DMLP Stock Earnings: Dorchester Minerals Reported Results for Q4 2023</a></li>



<li><a href="https://investorplace.com/earning-results/2024/03/mcrb-stock-earnings-seres-therapeutics-for-q4-of-2023/">MCRB Stock Earnings: Seres Therapeutics Beats EPS for Q4 2023</a></li>
</ul>On the date of publication, William White&nbsp;did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT793992">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/02/wall-street-legend-issues-urgent-ai-code-red/?cid=MKT781156&amp;eid=MKT793990">&ldquo;America&rsquo;s Top Trader&rdquo; Issues A.I. Code Red: Act Now or Miss Out</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793999">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/03/gold-price-alert-gold-spot-prices-just-hit-a-record-high-today/">Gold Price Alert: Gold Spot Prices Just Hit a Record High Today</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Gold Price Alert: Gold Spot Prices Just Hit a Record High Today

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Seres Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/mcrb-stock-quote/">MCRB</a>) just reported results for the fourth quarter of 2023.<ul><li>Seres Therapeutics reported earnings per share of -32 cents. This was above the analyst estimate for EPS of -50 cents.</li><li>The company reported revenue of $64,000.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/07/venture-capitalist-predicts-this-chatgpt-announcement-will-shock-the-world/?cid=MKT744191&amp;eid=MKT793994">ChatGPT IPO Could Shock the World, Make This Move Before the Announcement</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/02/wall-street-legend-issues-urgent-ai-code-red/?cid=MKT781156&amp;eid=MKT793989">&ldquo;America&rsquo;s Top Trader&rdquo; Issues A.I. Code Red: Act Now or Miss Out</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793998">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/03/mcrb-stock-earnings-seres-therapeutics-for-q4-of-2023/">MCRB Stock Earnings: Seres Therapeutics Beats EPS for Q4 2023</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

MCRB Stock Earnings: Seres Therapeutics Beats EPS for Q4 2023

Seres Therapeutics, Inc. (MCRB) Q4 2023 Earnings Call Transcript

TD Cowen analyst Joseph Thome maintained a Buy rating on Seres Therapeutics (MCRB – Research Report) yesterday. The company's shares closed yesterd...

Seres Therapeutics (MCRB) Gets a Buy from TD Cowen

Seres Therapeutics Inc. (MCRB) has disclosed a new risk, in the Supply Chain category. Seres Therapeutics Inc. is confronted with the business risk...

A New Cause for Concern: Seres Therapeutics Inc. Adds a New Supply Chain Risk

Oppenheimer analyst Jeff Jones maintained a Buy rating on Seres Therapeutics (MCRB – Research Report) today and set a price target of $5.00. The co...

Oppenheimer Sticks to Its Buy Rating for Seres Therapeutics (MCRB)

Seres Therapeutics Inc (MCRB) is up Thursday morning, with the stock increasing 0.99% in pre-market trading to 1.02. MCRB's short-term technical score of 1 indicates that the stock has traded less bullishly over the last month than 99% of stocks on the market. In the Biotechnology industry, which ranks 89 out of 146 indust

Seres Therapeutics Inc (MCRB) is up 0.99% Thursday In Premarket Trading

DMLP

MNTS

Biotech With Potential: Coeptis Therapeutics (COEP) And 3 Underrated Gems

Press Releases

Seres Therapeutics Announces the Appointment of Marella Thorell as Chief Financial Officer and the Retirement of David Arkowitz

Seres Therapeutics to Participate in Cowen 44th Annual Healthcare Conference

Seres Therapeutics to Host Fourth Quarter 2023 Financial Results and Operational Progress Conference Call and Webcast on March 5, 2024

Seres Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

Flagship Pioneering Named to Fast Company's Annual List of the World's Most Innovative Companies of 2024

Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio Sciences

Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Seres Therapeutics Stock (NASDAQ:MCRB), Short Interest Report

People Also Watch